In a post hoc analysis of the phase 3 ATTRibute-CM trial (611 participants with ATTR-CM), more patients on acoramidis than placebo reached clinically meaningful improvement in NT-proBNP or 6-minute walk distance at month 30 (22.7% vs 8.9%; OR 3.0, 95% CI 1.8-5.1).
Secondary analysisn = 611
Cappelli et al. Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM